Bone Related Events in High Risk Prostate Cancer

Journal of Urology

Volumn 176, Issue 6 SUPPL., 2006, Pages

  Srinivas, Sandy ^a   Colocci, Natalia ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

androgen antagonists; bone and bones; osteoporosis; prostate; prostatic neoplasms

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTRADIOL; PAMIDRONIC ACID; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TOREMIFENE; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; ARTICLE; BEHAVIOR MODIFICATION; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE NECROSIS; BONE TURNOVER; CALCIUM INTAKE; CANCER PATIENT; CANCER RISK; DIET SUPPLEMENTATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FAMILY HISTORY; FRACTURE; GYNECOMASTIA; HUMAN; HYPOGONADISM; LIFESTYLE; MASTALGIA; OSTEOLYSIS; OSTEOPENIA; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

BONE DENSITY; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33750483635     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.06.076     Document Type: Article

References (46)

1. Hanks G.E., Hanlon A.L., Pinover W.H., Horwitz E.M., Price R.A., and Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46 (2000) 823
2. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295
3. Moyad M.A. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol 23 (2005) 56
4. Orwoll E.S. Osteoporosis in men. Endocrinol Metab Clin North Am 27 (1998) 349
5. Smith M.R., McGovern F.J., Fallon M.A., Schoenfeld D., Kantoff P.W., and Finkelstein J.S. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91 (2001) 2238
6. Wei J.T., Gross M., Jaffe C.A., Gravlin K., Lahaie M., Faerber G.J., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54 (1999) 607
7. Kaufman J.M., Johnell O., Abadie E., Adami S., Audran M., Avouac B., et al. Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 59 (2000) 765
8. Smith M.R. Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treat Rev 29 (2003) 211
9. Smith M.R. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 20 (2003) 175
10. Berruti A., Dogliotti L., Terrone C., Cerutti S., Isaia G., Tarabuzzi R., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167 (2002) 2361
11. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., and Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008
12. Stepan J.J., Lachman M., Zverina J., Pacovsky V., and Baylink D.J. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 69 (1989) 523
13. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol 157 (1997) 439
14. Oefelein M.G., Ricchuiti V., Conrad W., Seftel A., Bodner D., Goldman H., et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166 (2001) 1724
15. Townsend M.F., Sanders W.H., Northway R.O., and Graham Jr. S.D. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79 (1997) 545
16. Hatano T., Oishi Y., Furuta A., Iwamuro S., and Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86 (2000) 449
17. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154
18. Smith M.R., Finkelstein J.S., McGovern F.J., Zietman A.L., Fallon M.A., Schoenfeld D.A., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87 (2002) 599
19. Fried L.P., Tangen C.M., Walston J., Newman A.B., Hirsch C., Gottdiener J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56 (2001) M146
20. Cummings S.R., Black D.M., Nevitt M.C., Browner W., Cauley J., Ensrud K., et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341 (1993) 72
21. Seeley D.G., Browner W.S., Nevitt M.C., Genant H.K., Scott J.C., and Cummings S.R. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 115 (1991) 837
22. Demers L.M., Costa L., Chinchilli V.M., Gaydos L., Curley E., and Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 41 (1995) 1489
23. Coleman R.E. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94 (2002) 2521
24. Brown J.E., Thomson C.S., Ellis S.P., Gutcher S.A., Purohit O.P., and Coleman R.E. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89 (2003) 2031
25. Samma S., Kagebayashi Y., Yasukawa M., Fukui Y., Ozono S., Hirao Y., et al. Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study. Jpn J Clin Oncol 27 (1997) 26
26. Ravn P., Hosking D., Thompson D., Cizza G., Wasnich R.D., McClung M., et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84 (1999) 2363
27. Rosen H.N., Moses A.C., Garber J., Iloputaife I.D., Ross D.S., Lee S.L., et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66 (2000) 100
28. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 1051
29. Bilezikian J.P. Osteoporosis in men. J Clin Endocrinol Metab 84 (1999) 3431
30. Heidenreich A. Bisphosphonates in the management of metastatic prostate cancer. Oncology, suppl. 65 (2003) 5
31. Diamond T.H., Winters J., Smith A., De Souza P., Kersley J.H., Lynch W.J., et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92 (2001) 1444
32. Smith M.R., McGovern F.J., Zietman A.L., Fallon M.A., Hayden D.L., Schoenfeld D.A., et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948
33. Slemenda C.W., Longcope C., Zhou L., Hui S.L., Peacock M., and Johnston C.C. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100 (1997) 1755
34. Barrett-Connor E., Mueller J.E., von Muhlen D.G., Laughlin G.A., Schneider D.L., and Sartoris D.J. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85 (2000) 219
35. Hedlund P.O., and Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 55 (2000) 328
36. Ockrim J.L., Lalani e.-N., Kakkar A.K., and Abel P.D. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 174 (2005) 527
37. Ockrim J.L., Lalani E.N., Banks L.M., Svensson W.E., Blomley M.J., Patel S., et al. Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 172 (2004) 2203
38. Ockrim J.L., Lalani E.N., Laniado M.E., Carter S.S., and Abel P.D. Transdermal estradiol therapy for advanced prostate cancer: forward to the past?. J Urol 169 (2003) 1735
39. Bland L.B., Garzotto M., DeLoughery T.G., Ryan C.W., Schuff K.G., Wersinger E.M., et al. Phase II study of transdermal estradiol in androgen independent prostate carcinoma. Cancer 103 (2005) 717
40. Smith M.R., Fallon M.A., Lee H., and Finkelstein J.S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 3841
41. Smith M.R. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 60 (2002) 79
42. Sieber P.R., Keiller D.L., Kahnoski R.J., Gallo J., and McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 171 (2004) 2272
43. McLeod D.G., Iversen P., See W.A., Morris T., Armstrong J., and Wirth M.P. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97 (2006) 247
44. Hoff A., Toth B., Altundag K., Guarneri V., Nooka A., Desrouleaux K., et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy (2005), Presented at meeting of American Society for Bone and Mineral Research, Nashville, Tennessee September 23-27
45. Higano C.S. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 31 (2004) 331
46. Hillner B.E., Ingle N.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042